Novo Nordisk aims to launch more than five blockbuster drugs by 2030, according to its Chief Executive Officer, as the Danish pharmaceutical giant prepares for upcoming patent expirations for semaglutide, … Read More
Semaglutide Beyond Obesity: Navigating the New Clinical Frontier Semaglutide has firmly entrenched itself in the public consciousness as a transformative weapon against obesity, but clinical research reveals its therapeutic footprint … Read More
Originally developed for type 2 diabetes and subsequently used to treat obesity, glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being investigated for a wide…
Researchers in Denmark have launched clinical trials investigating whether weight-loss injections like Wegovy can treat alcohol use disorder. Assessing 108 obese patients, the studies evaluate if glucagon-like peptide-1 receptor agonists … Read More
Researchers are investigating whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications currently approved for obesity and type 2 diabetes, can be repurposed to treat Alzheimer’s disease (AD). While these drugs … Read More
